GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (BUE:GILD) » Definitions » Sale Of Property, Plant, Equipment

Gilead Sciences (BUE:GILD) Sale Of Property, Plant, Equipment : ARS0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Gilead Sciences Sale Of Property, Plant, Equipment?

Gilead Sciences's sale of property, plant, equipment for the three months ended in Mar. 2024 was ARS0 Mil. It means Gilead Sciences gained ARS0 Mil from selling property, plant, and equipment. Gilead Sciences's sale of property, plant, equipment for the trailing twelve months (TTM) ended in Mar. 2024 was ARS0 Mil.

Compared with last quarter (ARS0 Mil in Dec. 2023 ), Gilead Sciences gained the same money from selling property, plant, and equipment in Mar. 2024 (ARS0 Mil).

Gilead Sciences Sale Of Property, Plant, Equipment Historical Data

The historical data trend for Gilead Sciences's Sale Of Property, Plant, Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Sale Of Property, Plant, Equipment Chart

Gilead Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sale Of Property, Plant, Equipment
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Gilead Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Sale Of Property, Plant, Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Gilead Sciences Sale Of Property, Plant, Equipment Calculation

The amount earned to sell PPE.

Sale Of Property, Plant, Equipment for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gilead Sciences Sale Of Property, Plant, Equipment Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Sale Of Property, Plant, Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.

Gilead Sciences (BUE:GILD) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (BUE:GILD) » Definitions » Sale Of Property, Plant, Equipment
Comparable Companies
BMY BIIB PFE AMGN OGN AMRN SCLX MIRA ABBV MRK LLY JNJ LSE:AZN XSWX:NOVN XSWX:ROG XPAR:SAN LSE:GSK TSE:4568 TSE:4519 SHSE:600276
Traded in Other Exchanges
GILD:USA GILD:Mexico GILD:Italy GISd:UK 0QYQ:UK GIS:Germany GIS:Germany GIS:Germany GIS:Germany GILD34:Brazil GILD:Austria
Address
333 Lakeside Drive, Foster, CA, USA, 94404
Website
https://www.gilead.com
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.